Table 1:

Baseline demographics of entire psoriasis cohort.

Parameters	Psoriasis (N = 164)
Demographics and medical history
Age, years	50.0 ± 12.9
Males	91 (55%)
Ethnicity, Caucasians	133 (81%)
Hypertension	45 (27%)
Hyperlipidemia	77 (47%)
Type 2 diabetes mellitus	16 (10%)
Current tobacco use	15 (9%)
Lipid treatment	53 (32%)
Body mass index	29.6 ± 6.1
Waist-to-hip ratio	0.95 (0.88 - 1.00)
Clinical and laboratory values
Systolic blood pressure, mmHg	123.6 ± 15.4
Diastolic blood pressure, mmHg	72.4 ± 10.2
Total cholesterol, mg/dL	181.5 ± 36.7
HDL cholesterol, mg/dL	55.7 ± 17.5
LDL cholesterol, mg/dL	101.2 ± 30.6
Triglycerides, mg/dL	121.8 ± 75.3
Framingham risk score	3.0 (1.0 – 6.0)
C-reactive protein, mg/L	2.0 (0.8 - 4.4)
HOMA-IR*	2.8 (1.7 – 4.7)
Cholesterol efflux capacity	0.95 ± 0.15
Psoriasis characterization
Psoriasis area severity index score	5.6 (3.0 – 9.6)
Total body surface area index	4.1 (2.4 – 13.5)
Systemic or biologic treatment	60 (37%)
Amygdalar activity (18FDG PET/CT)
Amygdalar FDG uptake	1.10 ± 0.11
Aortic vascular inflammation (18FDG PET/CT)
Target-to-background ratio	1.71 ± 0.26
Coronary plaque burdens (x100)
Total burden, mm2	1.14 ± 0.45
Non-calcified burden, mm2	1.10 ± 0.44
Hematopoietic system activity (18FDG PET/CT)
Bone marrow (SUV† max)	3.93 ± 0.93
Spleen (SUV† max)	3.47 ± 0.75

Values reported in the table as Mean ± SD or Median (IQR) for continuous data and N (%) for categorical data.

^*HOMA-IR: Homeostasis model assessment of insulin resistance,

^†SUV: Standardized uptake value.